703 related articles for article (PubMed ID: 7702398)
21. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
22. Raised serum APRIL levels in patients with systemic lupus erythematosus.
Koyama T; Tsukamoto H; Miyagi Y; Himeji D; Otsuka J; Miyagawa H; Harada M; Horiuchi T
Ann Rheum Dis; 2005 Jul; 64(7):1065-7. PubMed ID: 15576416
[TBL] [Abstract][Full Text] [Related]
23. Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus.
Colasanti T; Maselli A; Conti F; Sanchez M; Alessandri C; Barbati C; Vacirca D; Tinari A; Chiarotti F; Giovannetti A; Franconi F; Valesini G; Malorni W; Pierdominici M; Ortona E
Arthritis Rheum; 2012 Mar; 64(3):778-87. PubMed ID: 21968947
[TBL] [Abstract][Full Text] [Related]
24. Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus.
Sun J; Li X; Zhou H; Liu X; Jia J; Xie Q; Peng S; Sun X; Wang Q; Yi L
J Immunol Res; 2019; 2019():7430780. PubMed ID: 31049359
[TBL] [Abstract][Full Text] [Related]
25. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices.
Hegazy M; Darwish H; Darweesh H; El-Shehaby A; Emad Y
Clin Immunol; 2010 Apr; 135(1):118-24. PubMed ID: 20116334
[TBL] [Abstract][Full Text] [Related]
26. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Becker-Merok A; Nikolaisen C; Nossent HC
Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
[TBL] [Abstract][Full Text] [Related]
27. Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity.
Li Y; Jia R; Liu Y; Tang S; Ma X; Shi L; Zhao J; Hu F; Li Z
Lupus; 2020 Mar; 29(3):239-247. PubMed ID: 31930936
[TBL] [Abstract][Full Text] [Related]
28. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients.
Katsumata Y; Miyake K; Kawaguchi Y; Okamoto Y; Kawamoto M; Gono T; Baba S; Hara M; Yamanaka H
Arthritis Rheum; 2011 Aug; 63(8):2436-44. PubMed ID: 21506094
[TBL] [Abstract][Full Text] [Related]
29. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
30. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
Pradhan VD; Patwardhan MM; Ghosh K
Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543
[TBL] [Abstract][Full Text] [Related]
31. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus.
Reichlin M; Fesmire J; Quintero-Del-Rio AI; Wolfson-Reichlin M
Arthritis Rheum; 2002 Nov; 46(11):2957-63. PubMed ID: 12428237
[TBL] [Abstract][Full Text] [Related]
32. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
Russo K; Hoch S; Dima C; Varga J; Teodorescu M
J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
[TBL] [Abstract][Full Text] [Related]
33. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus.
Schneebaum AB; Singleton JD; West SG; Blodgett JK; Allen LG; Cheronis JC; Kotzin BL
Am J Med; 1991 Jan; 90(1):54-62. PubMed ID: 1986591
[TBL] [Abstract][Full Text] [Related]
34. Anti-cyclic citrullinated peptide antibodies and joint involvement in Behçet's disease.
Cho SB; Lee JH; Ahn KJ; Bae BG; Kim T; Park YB; Lee SK; Lee KH; Bang D
Yonsei Med J; 2012 Jul; 53(4):759-64. PubMed ID: 22665343
[TBL] [Abstract][Full Text] [Related]
35. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance.
Schnabel A; Csernok E; Isenberg DA; Mrowka C; Gross WL
Arthritis Rheum; 1995 May; 38(5):633-7. PubMed ID: 7748219
[TBL] [Abstract][Full Text] [Related]
36. Increased titres of IgM anti-heparan sulfate antibody in Behçet's disease.
Briani C; Doria A; Marcolongo R; Tognon S; Ruggero S; Toffanin E; Ermani M; Ghirardello A; Zampieri S; Semenzato G
Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S104-7. PubMed ID: 17067438
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus.
Permin H; Wiik A
Acta Pathol Microbiol Scand C; 1978 Oct; 86C(5):245-9. PubMed ID: 309705
[TBL] [Abstract][Full Text] [Related]
38. [Prevalence of antiepithelial cell antibody in systemic vasculitis and identification of the target antigen thereof].
Zheng WJ; Tang FL; Zhao Y; Chen H; Dong Y
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3272-6. PubMed ID: 16409818
[TBL] [Abstract][Full Text] [Related]
39. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
40. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
